Evaluation of in vitro activity of ceftolozane-tazobactam in combination with other classes of antibacterial agents against Enterobacterales and Pseudomonas aeruginosa—the EM200 study

Evaluation of in vitro activity of ceftolozane-tazobactam in combination with other classes of antibacterial agents against Enterobacterales and Pseudomonas aeruginosa—the EM200 study

Ceftolozane-tazobactam is a cephalosporin/β-lactamase inhibitor combination developed for use against some β-lactam- and multidrug-resistant Gram-negative organisms. This study aimed to evaluate the in vitro activity of ceftolozane–tazobactam against clinical bacterial isolates at the University Hos...

Full description

Bibliographic Details
Main Authors:	J. Belkhair, S. Nachat, S. Rouhi, H. Ouassif, S. Abbassi, N. Soraa
Format:	Article
Language:	English
Published:	Elsevier 2021-05-01
Series:	New Microbes and New Infections
Subjects:	Antimicrobial susceptibility ceftolozane-tazobactam Enterobacterales minimum inhibitory concentrations Pseudomonas aeruginosa
Online Access:	http://www.sciencedirect.com/science/article/pii/S2052297521000366

Similar Items

Clinical and microbiological features of ceftolozane/tazobactam-resistant Pseudomonas aeruginosa isolates in a university hospital in central Italy
by: Gianluca Morroni, et al.
Published: (2022-09-01)

Activity of Ceftolozane-Tazobactam Against Gram-Negative Isolates from Australia and New Zealand as part of the PACTS Surveillance 2016-2018
by: Dee Shortridge, et al.
Published: (2022-12-01)

Evaluation of ceftolozane-tazobactam susceptibility on a French nationwide collection of Enterobacterales
by: Agnès B. Jousset, et al.
Published: (2023-03-01)

Comparative In Vitro Activity of Ceftolozane/Tazobactam against Clinical Isolates of <i>Pseudomonas aeruginosa</i> and <i>Enterobacterales</i> from Five Latin American Countries
by: Juan Carlos García-Betancur, et al.
Published: (2022-08-01)

Ceftolozane/Tazobactam Activity Against Drug-Resistant Pseudomonas aeruginosa and Enterobacterales Causing Healthcare-Associated Infections in Eight Asian Countries: Report from an Antimicrobial Surveillance Program (2016–2018)
by: Pfaller M, et al.
Published: (2022-11-01)

Ceftolozane-tazobactam vs. colistin for the treatment of infections due to multidrug-resistant Pseudomonas aeruginosa: a multicentre cohort study
by: Thamer A. Almangour, et al.
Published: (2022-03-01)

Activity of ceftolozane/tazobactam against Gram-negative isolates from patients with lower respiratory tract infections – SMART United States 2018–2019
by: James A. Karlowsky, et al.
Published: (2021-03-01)

Tazobactam/ceftolozane and tobramycin combination therapy in extensively drug-resistant Pseudomonas aeruginosa infections in severe burn injury: a case report
by: Yuta Ibe, et al.
Published: (2023-08-01)

In Vitro Activity of Ceftolozane-Tazobactam and Other Antibiotics against <i>Pseudomonas aeruginosa</i> Infection-Isolates from an Academic Medical Center in Thailand
by: Woraphot Tantisiriwat, et al.
Published: (2022-05-01)

Temporal and geographical prevalence of carbapenem-resistant Pseudomonas aeruginosa and the in vitro activity of ceftolozane/tazobactam and comparators in Taiwan—SMART 2012–2021
by: James A. Karlowsky, et al.
Published: (2023-09-01)

Ceftolozane-tazobactam activity against clinical isolates of Pseudomonas aeruginosa from ICU patients with pneumonia: United States, 2015–2018
by: Michael A. Pfaller, et al.
Published: (2021-11-01)

Comparison of Ceftolozane/Tazobactam Infusion Regimens in a Hollow-Fiber Infection Model against Extensively Drug-Resistant Pseudomonas aeruginosa Isolates
by: María Milagro Montero, et al.
Published: (2022-06-01)

Activity of ceftolozane/tazobactam against clinical isolates of Pseudomonas aeruginosa from patients in the Middle East and Africa – Study for Monitoring Antimicrobial Resistance Trends (SMART) 2017-2020
by: Sibylle H. Lob, et al.
Published: (2022-12-01)

Molecular mechanisms leading to ceftolozane/tazobactam resistance in clinical isolates of Pseudomonas aeruginosa from five Latin American countries
by: María F. Mojica, et al.
Published: (2022-10-01)

Genomic Characterization of Mutli-Drug Resistant Pseudomonas aeruginosa Clinical Isolates: Evaluation and Determination of Ceftolozane/Tazobactam Activity and Resistance Mechanisms
by: Ibrahim Bitar, et al.
Published: (2022-06-01)

Real-world use of ceftolozane/tazobactam: a systematic literature review
by: Laura Puzniak, et al.
Published: (2021-04-01)

Ceftolozane/tazobactam – the "new player" in a battle against multiresistant pathogens
by: Golub A.V., et al.
Published: (2018-11-01)

Antimicrobial activities of ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/relebactam, meropenem/vaborbactam, and comparators against Pseudomonas aeruginosa from patients with skin and soft tissue infections
by: Helio S. Sader, et al.
Published: (2021-12-01)

Ceftolozane-Tazobactam Treatment of Hypervirulent Multidrug Resistant <i>Pseudomonas aeruginosa</i> Infections in Neutropenic Patients
by: Paolo E. Coppola, et al.
Published: (2020-12-01)

Antimicrobial Activity of Ceftolozane-Tazobactam, Ceftazidime-Avibactam, and Cefiderocol against Multidrug-Resistant Pseudomonas aeruginosa Recovered at a German University Hospital
by: C. Weber, et al.
Published: (2022-10-01)

Use of Ceftolozane/Tazobactam for the Treatment of Multidrug-Resistant <i>Pseudomonas aeruginosa</i> Pneumonia in a Pediatric Patient with Combined Immunodeficiency (CID): A Case Report from a Tertiary Hospital in Saudi Arabia
by: Ahmed Zikri, et al.
Published: (2019-05-01)

The Comparative Effectiveness of Ceftolozane/Tazobactam versus Aminoglycoside- or Polymyxin-Based Regimens in Multi-Drug-Resistant <i>Pseudomonas aeruginosa</i> Infections
by: Aisling R. Caffrey, et al.
Published: (2022-05-01)

Ceftolozane/Tazobactam In-Vitro Activity against Clinical Isolates from Complicated Intra-Abdominal Infection Patients in Three Indonesian Referral Hospitals
by: Anis Karuniawati, et al.
Published: (2022-12-01)

Treatment of multidrug-resistant Pseudomonas aeruginosa bacteremia using ceftolozane-tazobactam-based or colistin-based antibiotic regimens: A multicenter retrospective study
by: Hakeam A. Hakeam, et al.
Published: (2022-10-01)

Off-Label Use of Ceftolozane/Tazobactam for the Successful Treatment of Healthcare-Associated Meningitis Caused by Extensively Drug-Resistant <i>Pseudomonas aeruginosa</i> in a Polytraumatized Patient—A Case Report
by: Simon Dubler, et al.
Published: (2022-08-01)

SUSCETIBILIDADE DE ISOLADOS DE ENTEROBACTEREALES RESISTENTE AOS CARBAPENÊMICOS AOS ANTIBIÓTICOS CEFTAZIDIMA-AVIBACTAM, CEFTOLOZANE-TAZOBACTAM E CEFIDEROCOL
by: Deise Reis Carvalho, et al.
Published: (2023-10-01)

Chemical Stability of Ceftolozane/Tazobactam in Polyvinylchloride Bags and Elastomeric Pumps
by: Joseph Terracciano, PhD, et al.
Published: (2017-01-01)

Susceptibility of multi-drug resistant isolates of Pseudomonas aeruginosa to ceftazidime/aviabactam and ceftolozane/tazobactam in Benha University Hospital in Egypt and detection of carbapenemase genes
by: Sahar Fayed, et al.
Published: (2023-08-01)

Satisfactory In Vitro Activity of Ceftolozane<tt>–</tt>Tazobactam against Carbapenem-Resistant <i>Pseudomonas aeruginosa</i> But Not against <i>Klebsiella pneumoniae</i> Isolates
by: Alicja Sękowska, et al.
Published: (2023-03-01)

Best practices: Appropriate use of the new β-lactam/β-lactamase inhibitor combinations, ceftazidime-avibactam and ceftolozane-tazobactam in South Africa
by: Adrian J. Brink, et al.
Published: (2022-10-01)

Ceftolozane-tazobactam in combination with fosfomycin for treatment of MDR/XDR P. aeruginosa infective endocarditis
by: A. Prescott, et al.
Published: (2019-10-01)

Combined Resistance to Ceftolozane-Tazobactam and Ceftazidime-Avibactam in Extensively Drug-Resistant (XDR) and Multidrug-Resistant (MDR) <i>Pseudomonas aeruginosa</i>: Resistance Predictors and Impact on Clinical Outcomes Besides Implications for Antimicrobial Stewardship Programs
by: Marianna Meschiari, et al.
Published: (2021-10-01)

Ceftolozane/tazobactam for pulmonary exacerbation in a 63-year-old cystic fibrosis patient with renal insufficiency and an elevated MIC to Pseudomonas aeruginosa
by: Meredith Tate Romano, et al.
Published: (2020-01-01)

Real-Life Experience of Continuously Infused Ceftolozane/Tazobactam in Patients with Bronchiectasis and Multidrug-Resistant <i>Pseudomonas aeruginosa</i> Infection in the Outpatient Setting
by: Francesco Venuti, et al.
Published: (2023-07-01)

First Study of Antimicrobial Activity of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Against Pseudomonas aeruginosa Isolated from Patients with Urinary Tract Infection in Tehran, Iran
by: Rahimzadeh M, et al.
Published: (2020-02-01)

Extensively drug-resistant Pseudomonas aeruginosa: clinical features and treatment with ceftazidime/avibactam and ceftolozane/tazobactam in a tertiary care university hospital center in Portugal – A cross-sectional and retrospective observational study
by: Diogo Mendes Pedro, et al.
Published: (2024-02-01)

Influence of extracorporeal membrane oxygenation on the pharmacokinetics of ceftolozane/tazobactam: an ex vivo and in vivo study
by: Camille Mané, et al.
Published: (2020-05-01)

Ceftolozane/tazobactam for the treatment of complicated intra-abdominal and urinary tract infections: current perspectives and place in therapy
by: Escolà-Vergé L, et al.
Published: (2019-07-01)

Multicenter surveillance of antimicrobial susceptibilities and resistance mechanisms among Enterobacterales species and non-fermenting Gram-negative bacteria from different infection sources in Taiwan from 2016 to 2018
by: Shio-Shin Jean, et al.
Published: (2022-06-01)

In Vitro Activity of Ceftolozane-Tazobactam against <i>Escherichia coli</i>, <i>Klebsiella pneumoniae</i> and <i>Pseudomonas aeruginosa</i> Obtained from Blood Cultures from Sentinel Public Hospitals in South Africa
by: Olga Perovic, et al.
Published: (2023-02-01)